---
title: "Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration: Dosing and administration questions"
description: "Dosing and administration questions on Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing. Questions: What is the Vabysmo dosing schedule for wet AMD? 1 question quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vabysmo (faricimab-svoa) in neovascular age-related macular degeneration: Dosing and administration questions

Manufacturer: Genentech, Inc.  
Prescribing information: [Vabysmo](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf)

Dosing and administration questions that apply to every indication of Vabysmo are on [Vabysmo (faricimab-svoa), all indications: Dosing and administration](https://www.evicenter.com/medical-information/vabysmo/dosing-and-administration).

## Dosing

<a id="vabysmo-namd-dosing"></a>

### What is the Vabysmo dosing schedule for wet AMD?

> “The recommended dose for VABYSMO is 6 mg (0.05 mL of 120 mg/mL solution) administered 
> by intravitreal injection every 4 weeks (approximately every 28 ± 7 days, monthly) for the first 4 
> doses, followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks 
> later to inform whether to give a 6 mg dose via intravitreal injection on one of the following 
> three regimens: 1) Weeks 28 and 44; 2) Weeks 24, 36 and 48; or 3) Weeks 20, 28, 36 and 44. 
> Although additional efficacy was not demonstrated in most patients when VABYSMO was 
> dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week 
> (monthly) dosing after the first 4 doses. Patients should be assessed regularly.”

Source: [VABYSMO: Prescribing information, page 2, captured 2026-11-13](https://www.gene.com/download/pdf/vabysmo_prescribing.pdf#page=2)

> “Recommended dose for VABYSMO is 6 mg administered via one of three regimens<sup>1</sup>”

Source: [VABYSMO: Dosing & Administration in nAMD, captured 2026-11-13](https://www.vabysmo-hcp.com/dosing-and-administration-namd.html#:~:text=Recommended%20dose%20for%20VABYSMO%20is%206%20mg%20administered%20via%20one%20of%20three)

> “Although VABYSMO may need to be dosed as frequently as every 4 weeks after the first 4 doses, additional efficacy was not demonstrated in most patients compared to every 8 weeks.<sup>1</sup>”

Source: [VABYSMO: Dosing & Administration in nAMD, captured 2026-11-13](https://www.vabysmo-hcp.com/dosing-and-administration-namd.html#:~:text=Although%20VABYSMO%20may%20need%20to,patients%20compared%20to%20every%208)

> “Based on OCT and visual acuity evaluations 8 and 12 weeks later.<sup>1</sup>”

Source: [VABYSMO: Dosing & Administration in nAMD, captured 2026-11-13](https://www.vabysmo-hcp.com/dosing-and-administration-namd.html#:~:text=Based%20on%20OCT%20and%20visual%20acuity%20evaluations%208%20and%2012%20weeks)

## Related pages
- [Medical information: Vabysmo (faricimab-svoa): Neovascular age-related macular degeneration](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration)
- [Indication](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/vabysmo--neovascular-age-related-macular-degeneration/safety)
